
Product Data Sheet

Product Name: Hydroxytacrine (maleate)

Cat. No.: GC15604

Chemical Properties

Cas. No. 118909-22-1

Chemical Name 9-amino-1,2,3,4-tetrahydro-1-acridinol, 2Z-butenedioate

SMILES NC1=C2C(CCCC2O)=NC3=CC=CC=C31.OC(/C=C\C(O)=O)=O

Formula $C_{13}H_{14}N_2O \cdot C_4H_4O_4$ M.Wt 330.3

Solubility ≤ 30 mg/ml in DMSO; 2mg/ml in dimethyl formamide Storage Store at $-20^{\circ}C$

General tips For obtaining a higher solubility , please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Hydroxytacrine maleate, a bioactive monohydroxylated metabolite of cholinesterase inhibitor, is a potential Alzheimer's therapeutic of low toxicity [1]. Hydroxytacrine maleate exhibited biochemical and pharmacological profile similar to tacrine (THA) except that the far less liver toxicity in humans. The prolonged use of tacrine has been associated with liver toxicity[1, 2].

Hydroxytacrine maleate is a parasympathomimetic and a centrally acting cholinesterase inhibitor (anticholinesterase). As the first cholinesterase inhibitor approved for the treatment of AD, tacrine was marketed under the trade name Cognex [3]. Through hydroxylation of benzylic carbon by CYP450 in the liver, tacrine has been metabolized into metabolite 1-hydroxy-tacrine (velnacrine) [4]. It has also been shown that maleate is an inhibitor of AChE [5].

References:

[1]. D. Muoz-Torrero. Acetylcholinesterase inhibitors as disease-modifying therapies for

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Alzheimer's disease. *Curr. Med. Chem.* 15, 2433-2455 (2008).

[2]. E. Giacobini. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. *Neurochemistry International* 32, 413-419(1998).

[3]. Birks J S. Cholinesterase inhibitors for Alzheimer's disease[J]. *The Cochrane Library*, 2006.

[4]. Peng J Z, Remmel R P, Sawchuk R J. Inhibition of murine cytochrome P4501A by tacrine: in vitro studies[J]. *Drug metabolism and disposition*, 2004, 32(8): 805-812.

[5]. Acetylcholine and choline effects on erythrocyte nitrite and nitrate levels.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA